{"id":230663,"date":"2026-02-06T01:10:11","date_gmt":"2026-02-06T07:10:11","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/02\/next-generation-immune-profiling-beyond-blood-cancer-cells"},"modified":"2026-02-06T01:10:11","modified_gmt":"2026-02-06T07:10:11","slug":"next-generation-immune-profiling-beyond-blood-cancer-cells","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/02\/next-generation-immune-profiling-beyond-blood-cancer-cells","title":{"rendered":"Next-generation immune profiling \u2014 beyond blood cancer cells"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/next-generation-immune-profiling-beyond-blood-cancer-cells2.jpg\"><\/a><\/p>\n<p>Why immunoscores work in solid tumors\u2014but not yet in blood cancers\ud83d\udc47<\/p>\n<p>\u2705In solid tumors, immune profiling has reached a high level of standardization. Clear tumor boundaries allow quantification of immune cell infiltration, particularly CD3\u207a and CD8\u207a T cells, using immunohistochemistry. This has led to the development of validated immunoscores that stratify tumors as \u201chot,\u201d \u201ccold,\u201d or \u201cvery cold,\u201d providing robust prognostic and predictive value for immunotherapy response.<\/p>\n<p>\u2705These immunoscores work because solid tumors are spatially organized. Immune cells can be classified as infiltrating or excluded, and their density within defined tumor regions directly correlates with clinical outcome. As a result, immune cell infiltration has become a reliable biomarker to guide treatment decisions in cancers such as colon carcinoma.<\/p>\n<p>\u2705In contrast, hematologic malignancies lack these defining features. Leukemias and lymphomas are systemic diseases without clear tumor borders, making spatial immune assessment fundamentally challenging. Malignant and nonmalignant immune cells coexist within the same compartments, blurring the distinction between tumor cells and the immune microenvironment.<\/p>\n<p>\u2705Current immune profiling in hematologic cancers relies on baseline physiological levels of circulating or tissue-resident immune cells, including monocytes, neutrophils, T cells, NK cells, and B cells. While techniques such as flow cytometry, histology, and bulk or single-cell RNA sequencing provide rich datasets, they do not yet translate into a unified, clinically actionable immune score.<\/p>\n<p>\u2705This lack of standardization creates uncertainty in predicting immunotherapy responses. Metrics such as inflammation, cytotoxicity, or immune infiltration are difficult to interpret consistently across patients and disease subtypes, especially given systemic involvement and tissue-specific immune contexts.<\/p>\n<p>\ud83d\udca1<\/p>\n<div class=\"more-link-wrapper\"> <a class=\"more-link\" href=\"https:\/\/lifeboat.com\/blog\/2026\/02\/next-generation-immune-profiling-beyond-blood-cancer-cells\">Continue reading \u201cNext-generation immune profiling \u2014 beyond blood cancer cells\u201d | &gt;<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Why immunoscores work in solid tumors\u2014but not yet in blood cancers\ud83d\udc47 \u2705In solid tumors, immune profiling has reached a high level of standardization. Clear tumor boundaries allow quantification of immune cell infiltration, particularly CD3\u207a and CD8\u207a T cells, using immunohistochemistry. This has led to the development of validated immunoscores that stratify tumors as \u201chot,\u201d \u201ccold,\u201d [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,19],"tags":[],"class_list":["post-230663","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-chemistry"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/230663","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=230663"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/230663\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=230663"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=230663"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=230663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}